2m 2m 2m 2m 2m 2m 2m
IMMUNEERING-A (IMRX)
NASDAQ
$4.51-$0.04 (-0.99%)
Price as of Jun 03, 2026 7:58 PM EDT- $373.3MMarket Cap
- 132.14%1-Year Change
- BiotechnologyIndustry
IMMUNEERING-A (IMRX)
$4.51-$0.04 (-0.99%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | N/A N/A | N/A N/A | 0 -100.00% | 316,952 -84.76% | |
Cost of Revenue | N/A N/A | N/A N/A | 0 -100.00% | 158,122 -86.29% | |
Gross Profit | 0 N/A | 0 N/A | 0 -100.00% | 158,830 -82.86% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -42.0M -12.33% | -48.0M +15.23% | -41.6M +14.77% | -36.3M +36.65% | |
Depreciation and Amortization Expense | 29,267 0.00% | 29,267 0.00% | 29,267 -2.62% | 30,053 -33.90% | |
Total Operating Expenses | 59.4M -7.33% | 64.1M +9.69% | 58.4M +12.54% | 51.9M +49.09% | |
Operating Profit | -59.4M -7.33% | -64.1M +9.69% | -58.4M +12.89% | -51.7M +52.70% | |
Interest Income | 3.0M +17.20% | 2.6M -28.10% | 3.6M +255.56% | 1.0M +497.09% | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 3.0M +17.20% | 2.6M -28.10% | 3.6M +255.56% | 1.0M +497.09% | |
Total Nonoperating Income and Expense | 311,665 -29.41% | 441,493 -66.91% | 1.3M +515.31% | 216,844 +270.66% | |
Income before Taxes | -59.4M -7.33% | -64.1M +9.69% | -58.4M +15.64% | -50.5M +49.26% | |
Income Taxes | 0 N/A | N/A N/A | N/A N/A | -307,485 0.00% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -56.0M -8.21% | -61.0M +14.15% | -53.5M +5.86% | -50.5M +50.63% | |
Net Income from Continuing Operations Applicable to Common | -56.0M -8.21% | -61.0M +14.15% | -53.5M +5.86% | -50.5M +49.26% | |
Basic EPS and Net Income | -1.27 -37.75% | -2.04 +8.51% | -1.88 -1.57% | -1.91 -22.36% | |
Diluted EPS and Net Income | -1.27 -37.75% | -2.04 +8.51% | -1.88 -1.05% | -1.90 -22.76% | |
Basic Weighted Average Shares | 44.0M +46.80% | 30.0M +5.51% | 28.4M +7.69% | 26.4M +93.84% | |
Diluted Weighted Average Shares | 44.0M +46.80% | 30.0M +5.51% | 28.4M +7.69% | 26.4M +93.84% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 128.6M +255.92% | 36.1M -39.16% | 59.4M -18.22% | 72.6M -3.01% | |
Short-Term Investments | N/A N/A | 0 -100.00% | 26.3M -20.15% | 32.9M -55.74% | |
Cash and Cash Equivalents and Short-Term Investments | 128.6M +255.92% | 36.1M -57.81% | 85.7M -18.82% | 105.5M -29.27% | |
Total Current Assets | 176.2M +345.21% | 39.6M -55.56% | 89.1M -18.08% | 108.7M -28.61% | |
Accumulated Depreciation | 1.4M +29.66% | 1.1M +48.53% | 728,293 +74.09% | 418,337 +140.12% | |
Property and Plant and Equipment and Net | 938,481 -16.42% | 1.1M -19.83% | 1.4M +2.26% | 1.4M +69.67% | |
Total Long-Term Assets | 283,562 -78.12% | 1.3M +25.26% | 1.0M +39.09% | 743,703 +628.20% | |
Total Assets | 232.0M +340.08% | 52.7M -48.61% | 102.6M -16.17% | 122.4M -26.60% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 10.1M +34.25% | 7.5M -4.36% | 7.8M -2.59% | 8.1M +42.96% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 3.4M -10.38% | 3.8M -8.13% | 4.2M -6.72% | 4.5M -12.33% | |
Total Liabilities | 13.5M +19.18% | 11.3M -5.66% | 12.0M -4.06% | 12.5M +16.71% | |
Retained Earnings | -280.3M +24.98% | -224.3M +37.39% | -163.3M +48.70% | -109.8M +85.22% | |
Total Stockholders Equity | 218.5M +427.91% | 41.4M -54.31% | 90.6M -17.55% | 109.9M -29.57% | |
Total Shares Outstanding | 64.6M +108.20% | 31.1M -46.96% | 58.5M +121.60% | 26.4M +0.37% | |
Cash Flow | |||||
Cash from Operating Activities | -45.3M -17.55% | -55.0M +12.32% | -49.0M +11.04% | -44.1M +42.95% | |
Capital Expenditures | 142,226 +67.57% | 84,875 -75.24% | 342,746 -53.84% | 742,483 +1,121.47% | |
Cash from Investing Activities | -88.7M -435.69% | 26.4M +262.30% | 7.3M -82.56% | 41.8M +155.32% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 226.6M +4,172.32% | 5.3M -81.35% | 28.4M +149,558.35% | 19,004 -99.99% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | 50.11% N/A | |
Operating Margin | N/A N/A | N/A N/A | N/A N/A | -16,325.77% N/A | |
Return on Assets | -39.36% -49.93% | -78.61% +65.34% | -47.54% +36.03% | -34.95% N/A | |
Return on Equity | -43.12% -53.39% | -92.51% +73.37% | -53.36% +40.40% | -38.00% N/A | |
Revenue Growth | N/A N/A | N/A N/A | -100.00% +17.98% | -84.76% N/A | |
Current Ratio | 17.50 +231.63% | 5.28 -53.54% | 11.35 -15.90% | 13.50 N/A | |
Cash Ratio | 12.77 +165.12% | 4.82 -36.39% | 7.57 -16.04% | 9.02 N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow